Taxonomic group: fungi / Basidiomycota
(Phylum: Basidiomycota)
Associated disease: infection due to Cryptococcus neoformans [ICD11:
XN3EH 
]
Publication DOI: 10.1007/s40475-019-00178-xJournal NLM ID: 101625249Publisher: Cham, Switzerland: Springer International Publishing AG
Correspondence: nimrichter
micro.ufrj.br
Institutions: Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, USA, Veterans Administration Medical Center, Northport, USA, Instituto de Microbiologia Paulo de Góes (IMPG), Departamento de Microbiologia Geral, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil, Department of Medicine, Division of Infectious Diseases, Stony Brook University, Stony Brook, USA
Cryptococcus spp. are responsible for life-threatening infections in humans causing mortality rates of 70% in developing countries. Antifungal therapy to combat cryptococcosis is based on the combination of amphotericin B, azoles, and 5-flucytosine. However, treatment failure is frequently triggered by antifungal resistance, drug-drug interactions, and toxicity. New alternatives to prevent cryptococcosis are imperative. Here, we discuss the roles of lipids in the immunological control of the disease caused by Cryptococcus spp. Recently, remarkable advances on immunology of fungal infections have been made and a number of studies indicated the potential of vaccine formulations to combat cryptococcosis. New formulations exploiting virulence regulators and genetically modified attenuated strains have been tested. In this context, lipids have emerged as virulence regulators and immunogens to be explored. Glucosylceramide (GlcCer), sterylglycosides (SGs), and lipid-containing extracellular vesicles have been recently tested in vaccine formulations and their anticryptococcal efficacy was confirmed in vivo. Together, the data discussed here encourage the use of fungal lipids in anticryptococcal vaccinal strategies.
glucosylceramide, cryptococcosis, antifungal vaccine, immunogenic lipids, sterylglycosides, extracellular vesicles
Structure type: monomer
C
34H
56O
10Location inside paper: Fig. 1, b, right structure 1
Trivial name: ergosterol-β-D-glucopyranoside, ergosterol β-D-glucopyranoside
Compound class: saponin glycoside, glycoside, steroid glycoside, sterylglycoside
Contained glycoepitopes: IEDB_142488,IEDB_146664,IEDB_983931,SB_192
Enzymes that release or process the structure: sterylglucosidase
Related record ID(s): 50138, 50139, 50140
NCBI Taxonomy refs (TaxIDs): 5207Reference(s) to other database(s): GenDB:KT240140
Show glycosyltransferases
There is only one chemically distinct structure:
Found 
report error